Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response
Abstract Heat shock protein 90 (Hsp90) is a potential oncogenic target. However, Hsp90 inhibitors in clinical trial induce heat shock response, resulting in drug resistance and inefficiency. In this study, we designed and synthesized a series of novel triazine derivatives (A1‐26, B1‐13, C1‐23) as Hs...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2019-03-01
|
| Series: | ChemistryOpen |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/open.201900055 |
| _version_ | 1797771140055171072 |
|---|---|
| author | Dr. Peng Liu Dr. Xiangling Chen Dr. Jianming Zhu Dr. Bo Li Dr. Zhaoqiang Chen Dr. Guimin Wang Dr. Haiguo Sun Dr. Zhijian Xu Dr. Zhixin Zhao Dr. Chen Zhou Dr. Chengying Xie Prof. Liguang Lou Prof. Weiliang Zhu |
| author_facet | Dr. Peng Liu Dr. Xiangling Chen Dr. Jianming Zhu Dr. Bo Li Dr. Zhaoqiang Chen Dr. Guimin Wang Dr. Haiguo Sun Dr. Zhijian Xu Dr. Zhixin Zhao Dr. Chen Zhou Dr. Chengying Xie Prof. Liguang Lou Prof. Weiliang Zhu |
| author_sort | Dr. Peng Liu |
| collection | DOAJ |
| description | Abstract Heat shock protein 90 (Hsp90) is a potential oncogenic target. However, Hsp90 inhibitors in clinical trial induce heat shock response, resulting in drug resistance and inefficiency. In this study, we designed and synthesized a series of novel triazine derivatives (A1‐26, B1‐13, C1‐23) as Hsp90 inhibitors. Compound A14 directly bound to Hsp90 in a different manner from traditional Hsp90 inhibitors, and degraded client proteins, but did not induce the concomitant activation of Hsp72. Importantly, A14 exhibited the most potent anti‐proliferation ability by inducing autophagy, with the IC50 values of 0.1 μM and 0.4 μM in A549 and SK‐BR‐3 cell lines, respectively. The in vivo study demonstrated that A14 could induce autophagy and degrade Hsp90 client proteins in tumor tissues, and exhibit anti‐tumor activity in A549 lung cancer xenografts. Therefore, the compound A14 with potent antitumor activity and unique pharmacological characteristics is a novel Hsp90 inhibitor for developing anticancer agent without heat shock response. |
| first_indexed | 2024-03-12T21:33:13Z |
| format | Article |
| id | doaj.art-19113534e02f4f3c990ead9366f8a408 |
| institution | Directory Open Access Journal |
| issn | 2191-1363 |
| language | English |
| last_indexed | 2024-03-12T21:33:13Z |
| publishDate | 2019-03-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | ChemistryOpen |
| spelling | doaj.art-19113534e02f4f3c990ead9366f8a4082023-07-27T14:18:47ZengWiley-VCHChemistryOpen2191-13632019-03-018334435310.1002/open.201900055Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock ResponseDr. Peng Liu0Dr. Xiangling Chen1Dr. Jianming Zhu2Dr. Bo Li3Dr. Zhaoqiang Chen4Dr. Guimin Wang5Dr. Haiguo Sun6Dr. Zhijian Xu7Dr. Zhixin Zhao8Dr. Chen Zhou9Dr. Chengying Xie10Prof. Liguang Lou11Prof. Weiliang Zhu12Key Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaDivision of Anti-Tumor Pharmacology Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaDivision of Anti-Tumor Pharmacology Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaDivision of Anti-Tumor Pharmacology Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaDivision of Anti-Tumor Pharmacology Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaDivision of Anti-Tumor Pharmacology Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaKey Laboratory of Receptor Research Drug Discovery and Design Center Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 ChinaAbstract Heat shock protein 90 (Hsp90) is a potential oncogenic target. However, Hsp90 inhibitors in clinical trial induce heat shock response, resulting in drug resistance and inefficiency. In this study, we designed and synthesized a series of novel triazine derivatives (A1‐26, B1‐13, C1‐23) as Hsp90 inhibitors. Compound A14 directly bound to Hsp90 in a different manner from traditional Hsp90 inhibitors, and degraded client proteins, but did not induce the concomitant activation of Hsp72. Importantly, A14 exhibited the most potent anti‐proliferation ability by inducing autophagy, with the IC50 values of 0.1 μM and 0.4 μM in A549 and SK‐BR‐3 cell lines, respectively. The in vivo study demonstrated that A14 could induce autophagy and degrade Hsp90 client proteins in tumor tissues, and exhibit anti‐tumor activity in A549 lung cancer xenografts. Therefore, the compound A14 with potent antitumor activity and unique pharmacological characteristics is a novel Hsp90 inhibitor for developing anticancer agent without heat shock response.https://doi.org/10.1002/open.201900055autophagyHsp72Hsp90 inhibitortriazinesantitumor activity |
| spellingShingle | Dr. Peng Liu Dr. Xiangling Chen Dr. Jianming Zhu Dr. Bo Li Dr. Zhaoqiang Chen Dr. Guimin Wang Dr. Haiguo Sun Dr. Zhijian Xu Dr. Zhixin Zhao Dr. Chen Zhou Dr. Chengying Xie Prof. Liguang Lou Prof. Weiliang Zhu Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response ChemistryOpen autophagy Hsp72 Hsp90 inhibitor triazines antitumor activity |
| title | Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response |
| title_full | Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response |
| title_fullStr | Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response |
| title_full_unstemmed | Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response |
| title_short | Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response |
| title_sort | design synthesis and pharmacological evaluation of novel hsp90n terminal inhibitors without induction of heat shock response |
| topic | autophagy Hsp72 Hsp90 inhibitor triazines antitumor activity |
| url | https://doi.org/10.1002/open.201900055 |
| work_keys_str_mv | AT drpengliu designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drxianglingchen designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drjianmingzhu designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drboli designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drzhaoqiangchen designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drguiminwang designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drhaiguosun designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drzhijianxu designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drzhixinzhao designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drchenzhou designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT drchengyingxie designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT profliguanglou designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse AT profweiliangzhu designsynthesisandpharmacologicalevaluationofnovelhsp90nterminalinhibitorswithoutinductionofheatshockresponse |